Additionally, assuming that PD‐L1 expression status is associated with prognostic outcomes of EGFR–TKIs, there is sparse available evidence on how much PD‐L1 expression affects the prognostic outcomes in patients receiving EGFR–TKIs with EGFR‐mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.